Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

We evaluated safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics of AZD4831, a novel oral myeloperoxidase (MPO) inhibitor, in a randomized, single‐blind, placebo‐controlled study, following once‐daily multiple ascending dosing to steady‐state in healthy subjects. Target engagement was...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Transl Sci
Autores principales: Nelander, Karin, Lagerstrom‐Fermer, Maria, Amilon, Carl, Michaëlsson, Erik, Heijer, Maria, Kjaer, Magnus, Russell, Muir, Han, David, Lindstedt, Eva‐Lotte, Whatling, Carl, Gan, Li‐Ming, Ericsson, Hans
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8212712/
https://ncbi.nlm.nih.gov/pubmed/32770730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12859
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares